Skip to main content

Advertisement

SpringerLink
Log in

New Technologies Personalize Diagnostics and Therapeutics

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality in industrialized societies [10]. Efforts to reduce cardiovascular events in “high-risk” individuals or recurrent events in patients with established atherosclerotic cardiovascular disease emphasize broad-based implementation of guideline-directed therapeutic lifestyle changes and pharmacotherapy. Despite successful implementation of these evidence-based strategies, many individuals are not properly identified before their first event or they continue to experience cardiovascular events despite “optimal” levels of biomarkers. The application of genomics, proteomics, and metabolomics provides opportunities to improve our understanding of the complex process of atherosclerosis and enables personalized diagnostic and therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Redberg RF, Benjamin EJ, Bittner V, et al.; American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; Preventive Cardiovascular Nurses Association: ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women’s Health Research. Circulation 2009, 120:1296–1336.

    Article  PubMed  Google Scholar 

  2. Anderson JL, Adams CD, Antman EM, et al.: ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007, 50:e1–e157.

    Article  PubMed  Google Scholar 

  3. Seo D, Goldschmidt-Clermont P, Velazquez O, Beecham G: Genomics of premature atherosclerotic vascular disease. Curr Atherocler Rep 2010 (in press).

  4. Martinez-Pinna R, Barbas C, Blanco-Colio LM, et al.: Proteomic and metabolomic profiles in atherothrombotic vascular disease. Curr Atheroscler Rep 2010 (in press).

  5. Goonewardena SN, Prevette LE, Desai AA: Metabolomics and atherosclerosis. Curr Atheroscler Rep 2010 (in press).

  6. Ekroos K, Janis M, Tarsasov K, et al.: Lipidomics: a tool for studies on atherosclerosis. Curr Atheroscler Rep 2010 (in press).

  7. Kontush A, Chapman J: Lipidomics as a tool for study of lipoprotein metabolism. Curr Atheroscler Rep 2010 (in press).

  8. Rosenson RS, Rosenson RS: Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther 2009, 23:93–101.

    Article  PubMed  Google Scholar 

  9. Rosenson RS: Functional aspects of HDL: moving beyond static measures for risk assessment. Cardiovac Drugs Ther 2010 (in press).

  10. Jayagopal A, Linton MF, Fazio S, Haselton FR: Insights into atherosclerosis using nanotechnology. Curr Atheroscler Rep 2010 (in press).

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY, 10029-6574, USA

    Robert S. Rosenson

Authors
  1. Robert S. Rosenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert S. Rosenson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenson, R.S. New Technologies Personalize Diagnostics and Therapeutics. Curr Atheroscler Rep 12, 184–186 (2010). https://doi.org/10.1007/s11883-010-0103-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-010-0103-x

Keywords

Search

Navigation